SG11201808289SA - Binding molecules to cd38 and pd-l1 - Google Patents
Binding molecules to cd38 and pd-l1Info
- Publication number
- SG11201808289SA SG11201808289SA SG11201808289SA SG11201808289SA SG11201808289SA SG 11201808289S A SG11201808289S A SG 11201808289SA SG 11201808289S A SG11201808289S A SG 11201808289SA SG 11201808289S A SG11201808289S A SG 11201808289SA SG 11201808289S A SG11201808289S A SG 11201808289SA
- Authority
- SG
- Singapore
- Prior art keywords
- binding molecules
- molecules
- binding
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16305350 | 2016-03-25 | ||
| PCT/EP2017/057220 WO2017162890A1 (fr) | 2016-03-25 | 2017-03-27 | Molécules de liaison à cd38 et à pd-l1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201808289SA true SG11201808289SA (en) | 2018-10-30 |
Family
ID=55646510
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201808289SA SG11201808289SA (en) | 2016-03-25 | 2017-03-27 | Binding molecules to cd38 and pd-l1 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11505616B2 (fr) |
| EP (2) | EP3998285A1 (fr) |
| JP (2) | JP2019516396A (fr) |
| KR (1) | KR102361412B1 (fr) |
| CN (2) | CN109476741B (fr) |
| AU (1) | AU2017236183B2 (fr) |
| CA (1) | CA3022143A1 (fr) |
| DK (1) | DK3433273T3 (fr) |
| ES (1) | ES2906639T3 (fr) |
| HU (1) | HUE057657T2 (fr) |
| PL (1) | PL3433273T3 (fr) |
| PT (1) | PT3433273T (fr) |
| RU (1) | RU2764201C2 (fr) |
| SG (1) | SG11201808289SA (fr) |
| WO (1) | WO2017162890A1 (fr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110520444A (zh) * | 2017-01-09 | 2019-11-29 | 拜奥穆尼克斯制药 | 用于制备多特异性抗体的多肽接头 |
| AU2018241881A1 (en) * | 2017-03-27 | 2019-11-07 | Biomunex Pharmaceuticals | Stable multispecific antibodies |
| CN111819198A (zh) * | 2017-12-28 | 2020-10-23 | 尤利乌斯·马克西米利安维尔茨堡大学 | 具有非FcγR依赖性激动活性的肿瘤坏死因子(TNF)受体超家族(TNFRSF)受体-激活抗体融合蛋白(具有非FcγR依赖性激动活性的TNFRSF受体-激活抗体融合蛋白；TRAAFFIAA) |
| KR102471868B1 (ko) * | 2018-01-15 | 2022-11-30 | 아이-맵 바이오파마 유에스 리미티드 | 변형된 Cκ 및 CH1 도메인 |
| WO2019190327A2 (fr) | 2018-03-30 | 2019-10-03 | Merus N.V. | Anticorps multivalent |
| CA3116560A1 (fr) * | 2018-10-17 | 2020-04-23 | Immunome, Inc. | Anticorps bispecifiques ciblant des exosomes |
| UA128001C2 (uk) * | 2018-12-21 | 2024-03-06 | Ф. Хоффманн-Ля Рош Аг | Націлені на пухлину агоністичні cd28-антигензв'язувальні молекули |
| JP2022515424A (ja) | 2018-12-24 | 2022-02-18 | サノフイ | 突然変異ｆａｂドメインを有する多重特異性結合タンパク質 |
| WO2022150787A2 (fr) * | 2021-01-11 | 2022-07-14 | Adimab, Llc | Domaines ch1 variants et domaines cl variants ingéniérisés pour un appariement de chaînes préférentiel et anticorps multispécifiques les comprenant |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| DK2857516T3 (en) * | 2000-04-11 | 2017-08-07 | Genentech Inc | Multivalent antibodies and uses thereof |
| SI2511297T1 (sl) | 2004-02-06 | 2015-07-31 | Morphosys Ag | Proti -CD38 humana protitelesa in njihova uporaba |
| EP2535355B1 (fr) * | 2005-03-23 | 2019-01-02 | Genmab A/S | Anticorps dirigés contre CD38 pour le traitement du myélome multiple |
| TW201138821A (en) * | 2010-03-26 | 2011-11-16 | Roche Glycart Ag | Bispecific antibodies |
| WO2012088461A2 (fr) | 2010-12-23 | 2012-06-28 | Biogen Idec Inc. | Peptides coupleurs et polypeptides les comportant |
| EP2688909A2 (fr) | 2011-03-25 | 2014-01-29 | Glenmark Pharmaceuticals S.A. | Immunoglobulines hétéro-dimériques |
| EP2543680A1 (fr) | 2011-07-07 | 2013-01-09 | Centre National de la Recherche Scientifique | Fragment Fab d'anticorps multi-spécifiques mutés |
| US9428553B2 (en) | 2012-02-10 | 2016-08-30 | City Of Hope | Meditopes and meditope-binding antibodies and uses thereof |
| WO2014028776A1 (fr) * | 2012-08-15 | 2014-02-20 | Zyngenia, Inc. | Complexes multispécifiques monovalents et multivalents et leurs utilisations |
| US10047163B2 (en) | 2013-02-08 | 2018-08-14 | Abbvie Stemcentrx Llc | Multispecific constructs |
| CN105873953A (zh) | 2013-11-04 | 2016-08-17 | 格兰马克药品股份有限公司 | 重靶向t细胞的异源二聚免疫球蛋白的产生 |
| JP6775422B2 (ja) | 2014-03-28 | 2020-10-28 | ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． | Ｃｄ３８及びｃｄ３に結合する二重特異性抗体 |
| EP3143043B1 (fr) | 2014-05-16 | 2022-12-14 | Pfizer Inc. | Anticorps bispécifiques avec interfaces ch1-cl modifiees |
| EP3172235A2 (fr) | 2014-07-25 | 2017-05-31 | Cytomx Therapeutics Inc. | Anticorps anti-cd3, anticorps anti-cd3 activables, anticorps anti-cd3 multispécifiques, anticorps anti-cd3 activables multispécifiques et procédés d'utilisation de ces anticorps |
| WO2016172485A2 (fr) | 2015-04-24 | 2016-10-27 | Genentech, Inc. | Protéines multispécifiques de liaison à l'antigène |
| JP7258556B2 (ja) | 2016-04-28 | 2023-04-17 | ビオミューネクス・ファルマシューティカル | Ｅｇｆｒ及びｈｅｒ２をターゲティングする二重特異性抗体 |
| EP3494139B1 (fr) | 2016-08-05 | 2022-01-12 | F. Hoffmann-La Roche AG | Anticorps multivalents et multiépitopiques ayant une activité agoniste et procédés d'utilisation |
| CN110520444A (zh) | 2017-01-09 | 2019-11-29 | 拜奥穆尼克斯制药 | 用于制备多特异性抗体的多肽接头 |
| AU2018241881A1 (en) * | 2017-03-27 | 2019-11-07 | Biomunex Pharmaceuticals | Stable multispecific antibodies |
| SG11202002261VA (en) | 2017-09-22 | 2020-04-29 | Wuxi Biologics Ireland Ltd | Novel bispecific polypeptide complexes |
| GB201814562D0 (en) | 2018-09-07 | 2018-10-24 | Hummingbird Bioscience Pte Ltd | Vista antigen-binding molecules |
| US20190300610A1 (en) | 2018-03-29 | 2019-10-03 | Hummingbird Bioscience Pte. Ltd. | Vista antigen-binding molecules |
| WO2019185164A1 (fr) | 2018-03-29 | 2019-10-03 | Hummingbird Bioscience Holdings Pte. Ltd. | Molécules de liaison à l'antigène her3 |
| GB201913079D0 (en) | 2019-09-11 | 2019-10-23 | Hummingbird Bioscience Holdings Pte Ltd | Treatment and prevention of cancer using her3 antigen-binding molecules |
-
2017
- 2017-03-27 KR KR1020187030790A patent/KR102361412B1/ko active IP Right Grant
- 2017-03-27 ES ES17713672T patent/ES2906639T3/es active Active
- 2017-03-27 HU HUE17713672A patent/HUE057657T2/hu unknown
- 2017-03-27 CA CA3022143A patent/CA3022143A1/fr active Pending
- 2017-03-27 PL PL17713672T patent/PL3433273T3/pl unknown
- 2017-03-27 CN CN201780028279.6A patent/CN109476741B/zh active Active
- 2017-03-27 CN CN202310140318.9A patent/CN116284428A/zh active Pending
- 2017-03-27 AU AU2017236183A patent/AU2017236183B2/en active Active
- 2017-03-27 EP EP21214273.1A patent/EP3998285A1/fr active Pending
- 2017-03-27 PT PT177136728T patent/PT3433273T/pt unknown
- 2017-03-27 WO PCT/EP2017/057220 patent/WO2017162890A1/fr active Application Filing
- 2017-03-27 RU RU2018137419A patent/RU2764201C2/ru active
- 2017-03-27 EP EP17713672.8A patent/EP3433273B1/fr active Active
- 2017-03-27 DK DK17713672.8T patent/DK3433273T3/da active
- 2017-03-27 SG SG11201808289SA patent/SG11201808289SA/en unknown
- 2017-03-27 US US16/088,181 patent/US11505616B2/en active Active
- 2017-03-27 JP JP2019501761A patent/JP2019516396A/ja active Pending
-
2022
- 2022-05-25 JP JP2022085095A patent/JP2022116166A/ja active Pending
- 2022-11-17 US US18/056,279 patent/US20230146591A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US11505616B2 (en) | 2022-11-22 |
| CN109476741B (zh) | 2023-02-24 |
| DK3433273T3 (da) | 2022-02-14 |
| EP3433273B1 (fr) | 2021-12-29 |
| EP3433273A1 (fr) | 2019-01-30 |
| RU2018137419A3 (fr) | 2020-08-17 |
| KR20190016942A (ko) | 2019-02-19 |
| WO2017162890A1 (fr) | 2017-09-28 |
| ES2906639T3 (es) | 2022-04-19 |
| JP2019516396A (ja) | 2019-06-20 |
| HUE057657T2 (hu) | 2022-06-28 |
| PL3433273T3 (pl) | 2022-04-04 |
| CN116284428A (zh) | 2023-06-23 |
| KR102361412B1 (ko) | 2022-02-09 |
| EP3998285A1 (fr) | 2022-05-18 |
| AU2017236183A1 (en) | 2018-11-15 |
| RU2764201C2 (ru) | 2022-01-14 |
| AU2017236183B2 (en) | 2024-03-07 |
| CA3022143A1 (fr) | 2017-09-28 |
| PT3433273T (pt) | 2022-02-21 |
| JP2022116166A (ja) | 2022-08-09 |
| US20230146591A1 (en) | 2023-05-11 |
| CN109476741A (zh) | 2019-03-15 |
| RU2018137419A (ru) | 2020-04-27 |
| US20200010559A1 (en) | 2020-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL288012A (en) | Antibody molecules against lag-3 and their use | |
| IL263730A (en) | Binding molecules that bind pd-l1 and lag-3 | |
| IL251563A0 (en) | Antibody molecules to pd-l1 and their use | |
| IL249269A0 (en) | Trispecific molecules and methods of using them | |
| IL254223A (en) | CD20 binding compounds and their uses | |
| SG11201808289SA (en) | Binding molecules to cd38 and pd-l1 | |
| IL273641B (en) | Specific binding molecules for il-21 and uses thereof |